Table 1.
Baseline characteristics of the safety analysis set
| Characteristic | Safety analysis set [N = 1,790; n (%)] |
|---|---|
| Age, years | |
| Mean ± SD | 32.6 ± 11.3 |
| Range | 11–83 |
| Sex | |
| Male | 885 (49.4) |
| Comorbid disordersa | 736 (41.1) |
| Depression or depressive state | 377 (21.1) |
| Obsessive compulsive disorder | 58 (3.2) |
| Hepatic diseases | 47 (2.6) |
| Renal diseases | 7 (0.4) |
| Other | 489 (27.3) |
| Concomitant therapies | 1,349 (75.4) |
| Alprazolam | 361 (20.2) |
| Etizolam | 237 (13.2) |
| Ethyl loflazepate | 221 (12.3) |
| Mosapride citrate hydrate | 220 (12.3) |
| Sulpiride | 211 (11.8) |
| Mean daily dose of fluvoxamine, mg | |
| ≤25 | 65 (3.6) |
| 25–50 | 429 (24.0) |
| 50–75 | 277 (15.5) |
| 75–100 | 412 (23.0) |
| 100–125 | 150 (8.4) |
| 125–150 | 343 (19.2) |
| >150 | 109 (6.1) |
| Not known | 5 (0.3) |
| Total LSAS-J score | |
| ≤29 | 97 (5.4) |
| 30–59 | 384 (21.5) |
| 60–89 | 626 (35.0) |
| ≥90 | 536 (29.9) |
| Not assessed | 147 (8.2) |
All values are n (%) unless otherwise stated
LSAS-J Liebowitz Social Anxiety Scale-Japanese version, SD standard deviation
aData missing for 11 (0.6 %) patients